Intelligence Feed event · Equity · 2026-09-28

    HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830

    Question

    HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830

    Direct answer

    HUTCHMED has dosed the first subject in a global Phase Ia clinical study evaluating HMPL-A830 in patients with advanced solid tumors. The candidate represents a novel first-in-class therapy designed to overcome tumor resistance by concurrently targeting KRAS mutations and EGFR pathways via an antibody conjugate platform. The trial triggers clinical milestone progression under HUTCHMED's exclusive collaboration with GSK. Early safety, tolerability, and pharmacokinetics data from dose-escalation cohorts will inform Phase Ib expansion strategies in colorectal and non-small cell lung cancer cohorts.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-28
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830”, revision 1, evidence through 2026-09-28. https://marketontology.com/market-events/2026-09-28/hutchmed-begins-global-phase-ia-trial-for-kras-egfr-conjugate-hmpl-a830-d7bdda

    EQUITY
    HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830
    HUTCHMED has dosed the first subject in a global Phase Ia clinical study evaluating HMPL-A830 in patients with advanced solid tumors. The candidate represents a novel first-in-class therapy designed to overcome tumor resistance by concurrently targeting KRAS mutations and EGFR pathways via an antibody conjugate platform. The trial triggers clinical milestone progression under HUTCHMED's exclusive collaboration with GSK. Early safety, tolerability, and pharmacokinetics data from dose-escalation cohorts will inform Phase Ib expansion strategies in colorectal and non-small cell lung cancer cohorts.
    HCMGSK
    Impact
    64
    SEP 28
    SIG
    89%
    HCMGSK
    HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830
    HUTCHMED has dosed the first subject in a global Phase Ia clinical study evaluating HMPL-A830 in patients with advanced solid tumors. The candidate represents a novel first-in-class therapy designed to overcome tumor resistance by concurrently targeting KRAS mutations and EGFR pathways via an antibody conjugate platform. The trial triggers clinical milestone progression under HUTCHMED's exclusive collaboration with GSK. Early safety, tolerability, and pharmacokinetics data from dose-escalation cohorts will inform Phase Ib expansion strategies in colorectal and non-small cell lung cancer cohorts.
    → First-in-human clinical initiation for dual KRAS-EGFR conjugate therapy activates milestone progress under the GSK partnership, enhancing oncology pipeline asset valuation for HUTCHMED.
    Impact
    HUTCHMED has dosed the first subject in a global Phase Ia clinical study evaluating HMPL-A830 in patients with advanced solid tumors. The candidate represents a novel first-in-class therapy designed to overcome tumor resistance by concurrently targeting KRAS mutations and EGFR pathways via an antibody conjugate platform. The trial triggers clinical milestone progression under HUTCHMED's exclusive collaboration with GSK. Early safety, tolerability, and pharmacokinetics data from dose-escalation cohorts will inform Phase Ib expansion strategies in colorectal and non-small cell lung cancer cohorts.
    Affected
    HCMGSK
    Transmission
    First-in-human clinical initiation for dual KRAS-EGFR conjugate therapy activates milestone progress under the GSK partnership, enhancing oncology pipeline asset valuation for HUTCHMED.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMfirst-in-class clinical trial progression and milestone pipeline optionalityUp1-4wHUTCHMED initiated a Phase Ia global clinical trial of HMPL-A830 with first patient dosed September 24, 2026.
    GSKpartnered oncology pipeline advancementWatch1-3mExclusive development and commercialization partnership with HUTCHMED.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed14.13 2026-09-28+0.14%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month